Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29618335 | 1.00 | ALDH1A1 (0.48) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL11980453 | 0.95 | MEN1 (0.54) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL19996819 | 0.93 | MEN1 (0.52) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL24377317 | 0.93 | MEN1 (0.52) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL30811423 | 0.90 | KDM4E (0.41) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL25001630 | 0.90 | KDM4E (0.41) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL5837186 | 0.81 | KMT2A (0.59) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL3519553 | 0.81 | GRIN2D (0.40) | ALDH1A1KDM4EMEN1GAAMAPT | |
| SCHEMBL30311025 | 0.78 | PRKCG (0.31) | — | |
| SCHEMBL1506627 | 0.78 | PRKCG (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4371977-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023284837-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | 四川海思科制药有限公司 | 2023-01-19 | — | — | WO | disclosed |
| WO-2023284837-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | 四川海思科制药有限公司 | 2023-01-19 | — | — | WO | disclosed |
| WO-2022121805-A1 | FUSED RING COMPOUND AS NAV1.8 INHIBITOR AND USE THEREOF | 成都康弘药业集团股份有限公司 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022121805-A1 | FUSED RING COMPOUND AS NAV1.8 INHIBITOR AND USE THEREOF | 成都康弘药业集团股份有限公司 | 2022-06-16 | — | — | WO | disclosed |
| CN-114591293-A | Fused ring compound as Nav1.8 inhibitor and application thereof | 成都康弘药业集团股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
| EP-2694505-B1 | HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20090182001-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2009-07-16 | — | — | US | disclosed |
| US-20090042892-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-02-12 | — | — | US | disclosed |
| US-20090042892-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-02-12 | — | — | US | disclosed |
| US-20090018054-A1 | Cholesteryl Ester Transfer Protein Inhibitors | MERCK SHARP & DOHME LLC | 2009-01-15 | — | — | US | disclosed |
| EP-1973546-A2 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | Merck & Co., Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1971595-A2 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007081570-A2 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007081569-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-5530005-A | THERAPY FOR SKIN DISORDERS, AIDS, IMMUNOSUPPRESION DISEASES | SYNTEX (U.S.A.) INC. (US) | 1996-06-25 | — | — | US | disclosed |
| US-5475003-A | Antiinflammatory agent, immunosuppressive, antiallergens, bronchodilators, analgens | SYNTEX (U.S.A.) INC. (US) | 1995-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042892-A1 | Cetp Inhibitors | CETP, APOB, MTTP | ALDH1A1 3603/4885KDM4E 2213/4885MEN1 3533/4885 |
| US-20240208932-A1 | ARYLAMINO DERIVATIVE ESTROGEN RECEPTOR MODULATOR AND USE THEREOF | GPER1, ESR1, ESRRA | ALDH1A1 598/4885KDM4E 707/4885MEN1 4106/4885 |
| US-20090182001-A1 | Inhibitors of checkpoint kinases | CHEK1, CHEK2, BUB1B | ALDH1A1 2972/4885KDM4E 850/4885MEN1 969/4885 |
| US-20090018054-A1 | Cholesteryl Ester Transfer Protein Inhibitors | CETP, APOB, MTTP | ALDH1A1 1674/4885KDM4E 2924/4885MEN1 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.